Published in J Virol Methods on November 17, 2010
Molecular evidence of Ebola Reston virus infection in Philippine bats. Virol J (2015) 1.53
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Serological evidence of ebolavirus infection in bats, China. Virol J (2012) 1.32
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Ball python nidovirus: a candidate etiologic agent for severe respiratory disease in Python regius. MBio (2014) 0.85
Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses (2012) 0.84
Evaluation of RealStar Reverse Transcription-Polymerase Chain Reaction Kits for Filovirus Detection in the Laboratory and Field. J Infect Dis (2016) 0.84
Ebolavirus nucleoprotein C-termini potently attract single domain antibodies enabling monoclonal affinity reagent sandwich assay (MARSA) formulation. PLoS One (2013) 0.84
One-Step Reverse-Transcription FRET-PCR for Differential Detection of Five Ebolavirus Species. PLoS One (2015) 0.79
External quality assessment study for ebolavirus PCR-diagnostic promotes international preparedness during the 2014 - 2016 Ebola outbreak in West Africa. PLoS Negl Trop Dis (2017) 0.77
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis (2016) 0.76
Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol (2002) 6.60
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Rapid detection protocol for filoviruses. J Clin Virol (2004) 2.13
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis (2009) 2.07
Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis (1999) 2.04
Imported case of Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb Mortal Wkly Rep (2009) 1.90
Identification and analysis of Ebola virus messenger RNA. Virology (1987) 1.84
Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification. J Virol Methods (2006) 1.35
Development and evaluation of a fluorogenic 5'-nuclease assay to identify Marburg virus. Mol Cell Probes (2001) 1.14
Marburg haemorrhagic fever, Angola. Wkly Epidemiol Rec (2005) 0.98
Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J Clin Microbiol (2010) 0.95
Ebola haemorrhagic fever. A summary of the outbreak in Gabon. Wkly Epidemiol Rec (1997) 0.82
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis (2013) 4.92
Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (2006) 4.52
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis (2007) 3.47
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol (2006) 2.70
Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J Virol (2006) 2.60
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Pneumonia from human coronavirus in a macaque model. N Engl J Med (2013) 2.47
Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J Virol (2005) 2.45
Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A (2013) 2.29
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog (2009) 2.29
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
Polymorphisms and the differential antiviral activity of the chicken Mx gene. Genome Res (2002) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
The ecology of Ebola virus. Trends Microbiol (2007) 2.08
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer (2004) 2.04
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One (2013) 1.88
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A (2005) 1.85
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
Concern Serological evidence of Ebola virus infection in Indonesian orangutans. PLoS One (2012) 1.75
Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). Comp Med (2010) 1.71
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One (2010) 1.64
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005) 1.63
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis (2006) 1.62
Antibody-dependent enhancement of Ebola virus infection. J Virol (2003) 1.62
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol (2006) 1.61
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol (2010) 1.59
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep (2013) 1.55
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Reston Ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis (2011) 1.54
The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis (2011) 1.53
A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol (2011) 1.53
Reverse genetics for crimean-congo hemorrhagic fever virus. J Virol (2003) 1.52
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis (2012) 1.51
Species-independent detection of RNA virus by representational difference analysis using non-ribosomal hexanucleotides for reverse transcription. Nucleic Acids Res (2005) 1.51
Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol Cell Proteomics (2003) 1.49
Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology (2010) 1.48
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47